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Abstract
Purpose Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visual-
ization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-
phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of
the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG).
Methods Twenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer’s disease,
progressive supranuclear palsy, corticobasal syndrome,multi-system atrophy, Parkinson’s disease,multi-system atrophy, Parkinson's disease,
frontotemporal dementia) and received a dynamic [18F]PI-2620 tau-PET (0–60min p.i.) and static [18F]FDG-PET (30–50min p.i.). Regional
standardized uptake value ratios of early-phase images (single frame SUVr) and the blood flow estimate (R1) of [
18F]PI-2620-PET were
correlated with corresponding quantification of [18F]FDG-PET (global mean/cerebellar normalization). Reduced tracer uptake in cortical
target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three more and three less experienced
readers. Spearman rank correlation coefficientswere calculated between early-phase [18F]PI-2620 tau-PETand [18F]FDG-PETimages for all
cortical regions and frequencies of disagreement between images were compared for both more and less experienced readers.
Results Highest agreement with [18F]FDG-PET quantification was reached for [18F]PI-2620-PETacquisition from 0.5 to 2.5 min
p.i. for global mean (lowest R = 0.69) and cerebellar scaling (lowest R = 0.63). Correlation coefficients (summed 0.5–2.5 min
SUVr & R1) displayed strong agreement in all cortical target regions for global mean (RSUVr 0.76, RR1 = 0.77) and cerebellar
normalization (RSUVr 0.68, RR1 = 0.68). Visual interpretation revealed high regional correlations between early-phase tau-PET
and [18F]FDG-PET. There were no relevant differences between more and less experienced readers.
Conclusion Early-phase imaging of [18F]PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a
dual time-point protocol for tau-PET imaging could supersede additional [18F]FDG-PET imaging by indexing both the distri-
bution of tau and the extent of neuronal injury.
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Introduction
Tauopathies consist of neurodegenerative diseases in-
cluding, among others, Alzheimer’s disease (AD),
frontotemporal dementia and atypical parkinsonian syn-
dromes such as progressive supranuclear palsy (PSP)
and corticobasal syndrome (CBS), with the connective
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characteristic of misfolded and accumulated tau protein
in different parts of the brain [1, 2]. Visualization of tau
deposits in vivo has become possible with various tau-
targeting ligands for use with positron emission tomog-
raphy (PET) [3, 4]. While first-generation tau tracers
suffered from off-target binding [5, 6] and a resulting
large inter- and intra-case variability [7], second-
generation tau-PET tracers showed promising first re-
sults in vivo with specific binding in affected regions
in patients with mild cognitive impairment and AD
compared to healthy controls [8–11].
Tau-PET imaging complements an important biomarker
for the characterization of neurodegenerative diseases. For
AD, it has been proposed to classify the disease according
to the biomarkers for amyloid, tau and neuronal injury by
the A/T/N scheme [12]. In this classification scheme, neu-
ronal injury in the pathological definition can be deter-
mined in vivo by three different diagnostic approaches.
Atrophy in structural magnetic resonance tomography and
total tau in cerebrospinal fluid are considered as well as
hypometabolism in 18F-fluorodeoxyglucose ([18F]FDG)-
PET. This is underpinned by a combined study in prion
disease, indicating that metabolic imaging via [18F]FDG
correlates with neuropathologic changes including neuronal
loss [13].
For first-generation tau tracers and several tracers for
amyloid-PET imaging, it has been shown that the
perfusion-phase images as obtained by these tracers is
comparable to glucose metabolism as assessed by
[18F]FDG-PET and can therefore be used as surrogate
biomarker of neuronal injury [14–21]. With respect to
cost and radiation exposure, such “one-stop-shop” pro-
tocols have the opportunity to examine two important
biological markers with one procedure.
In contrast to amyloid imaging where the subjects
can only be classified as amyloid-positive or amyloid-
negative, tau-PET imaging shows characteristic patterns
for several different neurodegenerative entities [3].
Therefore, tau-PET imaging could probably also be used
to discriminate a range of tauopathies beyond AD. Due
to the lack of specificity of first-generation tau tracers,
it is of great interest whether and how the perfusion-
phase images as obtained by second-generation tracers
can be used as a marker of neuronal injury.
Thus, we aimed to investigate the potential of the second-
generation tau-PET ligand [18F]PI-2620 [22] as an additional
(in addition to detecting tau pathology) biomarker of neuronal
injury. We validated early-phase [18F]PI-2620 data against
[18F]FDG-PET and focused on optimizing dynamic or coffee
break acquisition protocols for tau-PET imaging with dual
biomarker information.
Materials and methods
Study design and patient enrolment
Patients with different suspected tauopathies were referred by
dementia or movement disorder experts to [18F]PI-2620 tau-
PET imaging. We selected all subjects with an additional
[18F]FDG-PET acquired < 12 months before/after tau-PET
imaging. The cohort consisted of patients with different
suspected clinical diagnoses and represented a true clinical
cross-section in a tertiary centre with a focus on dementia/
movement disorders. The most likely clinical differential di-
agnosis was recorded before [18F]PI-2620 tau-PET imaging.
All patients provided informed written consent to PET imag-
ing. The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki, and approval for scientific




Radiosynthesis of [18F]PI-2620 was achieved by nucleophilic
substitution on a BOC-protected nitro precursor using an au-
tomated synthesis module (IBA, Synthera). The protecting
group was cleaved under the radiolabelling conditions. The
product was purif ied by semipreparat ive HPLC.
Radiochemical purity was 99%. Non-decay corrected yields
were about 35% with a molar activity of 8∙106 GBq/mmol at
the end of synthesis. [18F]FDG was purchased commercially.
PET acquisition and preparation
All patients were scanned at the Department of Nuclear
Medicine, LMU Munich, with a Biograph 64 or a Siemens
mCT PET/CT scanner (both Siemens, Erlangen, Germany). A
low-dose CTscan preceded the PETacquisition and served for
attenuation correction. [18F]PI-2620-PET was performed in a
full dynamic 0–60-min setting initiated upon intravenous in-
jection (~ 10 s) of 185 ± 10 MBq of the ligand. [18F]PI-2620-
PET data were reconstructed in a series of 23 frames (6 ×
0.5 min, 4 × 1.0 min, 4 × 2.0 min, 9 × 5.0 min). [18F]-FDG-
PETwas acquired after injection of 125 ± 10 MBq [18F]FDG
according to the EANMprotocol [23]: fasting conditions > 6 h
with a blood glucose < 120 mg/dl (6.7 mm) at time of scan-
ning, silent room with dimmed light, headphones and blind-
fold 20 min prior and after injection. [18F]FDG-PET data was
reconstructed in a static 30–50-min frame. PET data were
reconstructed iteratively (4 iterations, 21 subsets, 5.0-mm
Gauss/5 iterations, 24 subsets, 5.0-mm Gauss) with a matrix
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size of 336 × 336 × 109/ 400 × 400 × 148, a voxel size of
1.018 × 1.018 × 2.027/1.018 × 1.018 × 1.500 mm3 and a slice
thickness of 2.027/1.500 mm. Standard corrections with re-
gard to scatter, decay and random counts were used. Both
reconstruction algorithms resulted in images with equal spatial
resolution (8 × 8 × 7 mm) as validated by Hofmann phantom
measures.
Image processing
All image data were processed and analysed using PMOD
(version 3.5, PMOD Technologies Ltd. , Zurich,
Switzerland). For spatial normalization, tracer-specific tem-
plates in the MNI space were created for [18F]PI-2620 (30–
60 min) and [18F]-FDG as described previously [14].
Dynamic [18F]PI-2620 images were coregistered to the MNI
space by applying the 30–60-min transformation (brain nor-
malization settings: nonlinear warping, 8-mm input smooth-
ing, equal modality, 16 iterations, frequency cut-off 3, regu-
larization 1.0, no thresholding). All images were analysed in
MNI space. The regional cerebral blood flow estimate R1 was
computed from the dynamic [18F]PI-2620 images by applying
the simplified reference tissue model 2 (SRTM2) as described
previously [24, 25], using the cerebellum (excluding the den-
tate nucleus and superior layers) as a reference region. A total
number of ten predefined cortical volumes (bilateral frontal,
central region, parietal, temporal, occipital) of interests (VOIs)
deriving from the Hammers atlas [26] were delineated in the
MNI space and standardized uptake value ratios (SUVr) of all
VOIs were extracted for the different images (and different
time frames) used for the analysis.
In preparation for visual analyses of all images (after selec-
tion of the appropriate time frame), dynamic data frames
#2-#5 (0.5–2.5 min) were summed. To account for the lower
count statistics of the early-phase images, an additional 6.0-




Correlation of single frames of [18F]PI-2620-PET versus [18F]
FDG-PET
The optimal early time window for [18F]PI-2620 early-phase
imaging in terms of maximal correlation to [18F]FDG-PET
was determined. To this end, [18F]PI-2620-PET SUVrs for
the ten cortical VOIs were extracted and correlated with the
SUVrs of the corresponding [18F]FDG-PET data after normal-
ization of uptake to global mean (GBM) or by use of a cere-
bellar reference region (CBL). Pearson’s correlation coeffi-
cients (R) were compared between different time frames and
the selection of the optimal early-phase time window was
based on the extent and significance of single frame
agreement.




The SUVr values of the optimized summed [18F]PI-2620
early-phase image (0.5–2.5 min), the [18F]PI-2620 R1 image
and the [18F]FDG image were correlated for all ten cortical
regions to investigate the regional relationship between tau-
PET perfusion and glucose metabolism.
Visual analysis of stereotactic surface projections
For visual interpretation of early-phase [18F]PI-26200.5–2.5min,
[18F]PI-2620R1 and [
18F]FDG-PET images, three-dimensional
stereotactic surface projections (3D-SSP) [27] were generated
using the software Neurostat (Department of Radiology,
University of Washington, Seattle, WA, USA). Voxel-wise Z-
scores were calculated in Neurostat by comparing the individ-
ual tracer uptake ([18F]PI-26200.5–2.5min, [
18F]PI-2620R1 and
[18F]FDG) to a historical [18F]FDG-PET database (cognitively
healthy individuals, age-matched, N = 18).
Three more experienced nuclear medicine physicians
(H.B., T.v.E., M.B.) and three less experienced nuclear
medicine interns (L.B., M.U., J.S.) visually assessed the
3D-SSP images using the Z-score maps (GBM scaling)
and rated cortical regions used in the clinical routine
(bilateral frontal, parietal, temporal, occipital cortex
areas) from 0 to 3 (0 = no reduction, 1 = low reduction,
2 = intermediate reduction, 3 = severe reduction 0.5 steps
were allowed). Furthermore, whole-brain 3D-SSP im-
ages were rated binary (0/1) and according to the sever-
ity of present neurodegeneration (0 = no/1 = mild/2 = in-
termediate/3 = severe neurodegeneration; 0.5 steps were
allowed). A significant neuronal injury of the patient
(A/T/N: N+) was defined by the majority read of
binarized [18F]FDG-PET evaluation by the three more
experienced physicians. Readers had access to the pre-




domly and blindly (with regard to the type of image)
presented to the readers.
Statistical analysis
Correlations of regional SUVr between early-phase
[18F]PI-2620 and [18F]FDG images were evaluated using
Pearson’s correlation coefficient (R) and R values were
compared using Fisher’s Z-transformation. Quantitative
Eur J Nucl Med Mol Imaging
variables were reported as mean ± standard deviation.
Comparison of R values for different normalization ap-
proaches was also performed by Fisher’s Z-transforma-
tion. For visual analysis and the specification of the most




calculated using Spearman’s rank correlation coefficients.




lated and evaluated as frequency of all brain regions. A
significance level of p < 0.05 was applied in all analyses.
All statistical analyses were performed using SPSS (ver-
sion 25.0, IBM, Armonk, New York, USA).
Results
Demographics
A total of 26 subjects (age = 66 ± 11 years, 17 female) were
included in the analysis. The cohort consisted of seven sub-
jects with a most likely diagnosis of AD, 13 subjects with
movement disorders and most likely diagnosis of PSP or
CBS, one case with most likely frontotemporal dementia,
two cases with most likely multi-system atrophy, two cases
with most likely Parkinson’s disease, and one case with cog-
nitive impairment of unknown reason. The mean time interval
between both PET investigations was 1.2 ± 1.7 months. For
Table 1 Demographics of the study population
All Most likely AD Most likely 4R-tauopathy Other
Number of subjects 26 7 13 6
Age (mean ± SD) 66.0 ± 10.7 67.4 ± 9.1 70.7 ± 6.8 54.2 ± 11.6
Gender (♂/ ♀) ♂ 9/♀ 17 ♂ 4/♀ 3 ♂ 4/♀ 9 ♂ 1/♀ 5
Time interval between PI-2620- and FDG-PET (months, mean ± SD) 1.2 ± 1.7 1.3 ± 1.8 1.2 ± 1.6 1.0 ± 2.0
Significant neuronal injury [18F]FDG (%, visual) 65 71 77 33
AD, Alzheimer’s disease; 4R, 4R-tauopathies (progressive supranuclear palsy, corticobasal syndrome); Other (frontotemporal dementia, multi-system
atrophy, Parkinson’s disease, unclear phenotype); SD, standard deviation. Significant neuronal injury in FDG-PETwas defined by the majority read of
more experienced readers
Fig. 1 a Averaged (across all
study subjects) time-activity
curve of [18F]PI-2620 in a cortical
composite volume of interest
during the dynamic data
acquisition. b Correlation
coefficients (R) between single
frames of [18F]PI-2620-PET and
[18F]FDG-PET (30–50 min p.i.).
GBM, global mean scaling; CBL,
cerebellar reference region. The
time-window used for further
analyses is highlighted in grey
Eur J Nucl Med Mol Imaging
details of the study population see Table 1. Visual binary in-
terpretation (majority read of more experienced readers) re-
vealed a significant neuronal injury to [18F]FDG-PET in 65%
of all cases.
Optimal time window for [18F]PI-2620-PET
early-phase imaging
The VOI-based comparison of single frames of [18F]PI-2620-
PET (6 × 0.5 min, 4 × 1.0 min, 4 × 2 min, 9 × 5.0 min) and
[18F]FDG-PET (30–50 min p.i.) revealed the highest agree-
ment for the frames #2–#5 lasting from 0.5–2.5 min after
injection for both global mean scaling (RGBM = 0.728) and a
cerebellar reference region (RCBL = 0.665; Fig. 1). The corre-
lation was statistically significant for all cortical regions for
frames #2–#7 for global mean scaling (0.5–4 min after injec-
tion), but frames #6–#7 showed overall lower correlation co-
efficients compared to frames #2–#5 (especially with a cere-
bellar reference region). Because of the fast wash-out and
sufficient count statistics for frames #2–#5, the mean values
of the 0.5–2.5 min p.i. time window (frames #2-#5) were used
for further semiquantitative and visual analyses. This was as
they represented the optimal trade-off between correlation
with the [18F]FDG-PET data and count statistics. The correla-
tion coefficients between the early [18F]PI-2620 and
[18F]FDG-PET data and their degree of significance for all
frames are shown in Table 2. The correlations coefficients
between both normalization approaches were not significantly
different (p = 0.301).
Semiquantitative VOI-based comparison
of early-phase [18F]PI-2620-PET and [18F]FDG-PET
The PET parameters in all cortical brain regions showed high-
ly significant correlations with [18F]FDG-PET for both early-
phase [18F]PI-2620-PET approaches (0.5–2.5 min and R1).
There was no significant difference in the correlation coeffi-
cients of [18F]PI-26200.5–2.5min and [
18F]PI-2620R1 with
[18F]FDG-PET (R0.5–2.5min = 0.762, RR1 = 0.766, p = 0.487)
for global mean normalization. The highest degree of correla-
tion was found in the right parietal cortex (R0.5–2.5min = 0.872,
RR1 = 0.884) and the weakest correlation was observed in the
left central region (R0.5–2.5min = 0.585, RR1 = 0.586). The
semiquantitative comparison of [18F]PI-26200.5–2.5min and
[18F]PI-2620R1 with [
18F]FDG-PET and cerebellar scaling al-
so showed significant, but overall weaker correlations when
Table 2 Correlation coefficients
between single frames of [18F]PI-
2620-PET and [18F]FDG-PET
Time frames (min post-injection) R pmax R pmax
Global mean normalization Cerebellar normalization
0–0.5 0.413 0.684 0.445 0.278
0.5–1.0 0.740 0.002** 0.650 0.036*
1.0–1.5 0.744 0.007** 0.679 0.019*
1.5–2.0 0.721 0.027* 0.665 0.021*
2.0–2.5 0.706 0.018* 0.667 0.041*
2.5–3.0 0.690 0.024* 0.610 0.073
3.0–4.0 0.677 0.042* 0.620 0.045*
4.0–5.0 0.599 0.071 0.550 0.225
5.0–6.0 0.573 0.225 0.519 0.086
6.0–7.0 0.506 0.520 0.452 0.140
7.0–9.0 0.405 0.493 0.309 0.294
9.0–11.0 0.322 0.692 0.184 0.954
11.0–13.0 0.190 0.984 − 0.005 0.895
13.0–15.0 0.155 0.983 − 0.018 0.995
15.0–20.0 0.040 0.968 − 0.082 0.912
20.0–25.0 0.009 0.621 − 0.110 0.875
25.0–30.0 − 0.047 0.970 − 0.149 0.873
30.0–35.0 − 0.021 0.909 − 0.137 0.961
35.0–40.0 − 0.039 0.911 − 0.136 0.850
40.0–45.0 − 0.055 0.748 − 0.144 0.702
45.0–50.0 − 0.082 0.961 − 0.139 0.937
50.0–55.0 − 0.070 0.683 − 0.126 0.983
55.0–60.0 − 0.117 0.955 − 0.162 0.804
FDG, fluorodeoxyglucose; R, correlation coefficient (Pearson, two-sided, Fisher’s Z-transformation of all re-
gions); pmax, maximum p value of all ten cortical regions. *p < 0.05, **p < 0.01
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compared to global mean normalization for all cortical regions




(all global mean normalization) are shown in Fig. 2.
Corresponding regional values and correlation coefficients deter-
mined by comparing regional [18F]PI-26200.5–2.5min and [
18F]PI-
2620R1 with [
18F]FDG-PET SUVr (global mean and cerebellar
normalization) are shown in Supplementary Table 1.
Visual 3D-SSP comparison of early-phase [18F]
PI-2620-PET and [18F]FDG-PET
After identification of the optimal time window, visual assess-
ment was performed by evaluating 3D-SSP images of early-
phase ([18F]PI-26200.5–2.5min and [
18F]PI-2620R1) and
[18F]FDG-PET (global mean normalization). Representative
images of early-phase [18F]PI-26200.5–2.5min, [
18F]PI-2620R1
and [18F]FDG-PET 3D-SSP and exemplary summed 0.5–2.5-
min section images for three different most likely diagnoses of
neurodegenerative disorders are shown in Fig. 3. In all cases,
the regional pattern of hypoperfusion in [18F]PI-26200.5–2.5min
and [18F]PI-2620R1 3D-SSP resembled the hypometabolism
pattern in [18F]FDG-PET. Furthermore, exemplary distribu-
tion volume ratio images of those cases with the specific
tau-PET binding pattern are shown in Supplementary Fig. 1.
Visual interpretation revealed moderate to high regional
correlations for the majority of regions between early-phase
tau-PET (both PI-26200.5–2.5min and PI-2620R1) and
[18F]FDG-PET (see Table 3).
The frequency of no or only minor disagreement was far
higher (0–0.5; 73–83%) when compared to the frequency of
moderate (1.0–1.5; 17–25%) or high disagreement (≥ 2.0; 1–
2%) regardless of using PI-26200.5–2.5min or PI-2620R1 for
early-phase assessment (Fig. 4). Frequencies of disagree-
ment were similar for more and less experienced readers
(compare Fig. 4a, b).
Discussion
Tau-PET imaging is of great interest as tauopathies make up
the majority of neurodegenerative diseases [28]. However, not
only information on tau-positivity but also on the presence of
neuronal injury is considered in current diagnosis or research
criteria of AD [12, 29] and non-AD tauopathies [30]. In ac-
cordance with previous amyloid-PET studies [14–18, 21], and
considering the known limitations of first-generation tau
radiotracers [19, 31], we aimed to evaluate the potential of
the early-phase of the second-generation tau-PET radiotracer
[18F]PI-2620 [11] as a potential surrogate biomarker of neu-
ronal injury. Our results demonstrate a strong quantitative and
visual agreement between reduced perfusion in tau-PET and
reduced glucose metabolism in [18F]FDG-PET imaging.
Therefore, early-phase tau-PET images may potentially elim-
inate the need for an additional [18F]FDG-PET. The ability to
obtain two different biomarkers reduces costs, time and radi-
ation exposure, and enables improved differential diagnosis
through a one-stop-shop procedure, which is especially im-
portant for disabled patients.
The semiquantitative comparison of [18F]PI-2620-PETsin-
gle frameswith individual [18F]FDG-PET images revealed the
highest agreement at 0.5–2.5 min after injection and decreased
steadily until it was no longer significant for all cortical re-
gions later than 4 min after injection. Previous studies evalu-
ating the agreement between early-phase amyloid-PET acqui-
sitions and [18F]FDG-PETsuggested time frames up to 10min
after injection, often sparing the first minute after injection
[14, 15, 17]. Compared to these studies, we can conclude that
the acquisition of early-phase [18F]PI-2620 must include a
very early and relatively short time frame to achieve a high
agreement between tau-PETand [18F]FDG-PET, likely related
to the fast washout of [18F]PI-2620 (Fig. 1a). Although the
frames between 0.5 and 4.0 min p.i. indicated a significant
correlation with [18F]FDG-PET, we recommend the use of
0.5 to 2.5 min p.i. for early-phase [18F]PI-2620 acquisition
as this time window was more robust across different scaling
methods. For implementation in study or clinical routine
workflows, dynamic or coffee break protocols (included break
between early- and late-image acquisitions with the possibility
for the patient to rest) could be considered. In this regard,
dynamic protocols will have the advantage of being able to
perform non-invasive kinetic modelling for the tau-PET read-
out, which will be important to account for blood flow chang-
es in longitudinal studies [32]. We also propose to exclude the
first half minute of acquisition, which showed more variabil-
ity, likely related to variance in blood flow (i.e., reduced car-
diac ejection fraction), site of injection, and variance of man-
ual injection. Therefore, we additionally calculated the region-
al cerebral blood flow estimate R1 of [
18F]PI-2620 to take
such individual differences into account and found similar
results by this approach. The VOI-based semiquantitative re-
gional correlation of both the summed early-phase (0.5–
2.5 min) and R1 of [
18F]PI-2620 showed a highly significant
correlation in all assessed cortical regions and no significant
advantage for one of the methods. For clinical implementa-
tion, the reconstruction of a summed image seems to be more
suitable as it can be easily added to conventional reconstruc-
tion algorithms of common PET systems.
All semiquantitative analyses were performed with global
mean normalization and whole cerebellum scaling. In
Fig. 2 Correlation charts of early-phase [18F]PI-26200.5–2.5min and
[18F]PI-2620R1 with [
18F]FDG-PET SUVr (all global mean
normalization). SUVr, standard-uptake-value-ratio; FRO, frontal;
CENT, central; PAR, parietal; TEMP, temp; OCC, occipital
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accordance with our previous investigation on early-phase
amyloid-PET [14], the cerebellar normalization approach
showed lower correlations for all investigated cortical regions.
Since cerebellar perfusion tends to be highly variable, e.g., as
a consequence of significant gender differences [33], a global
mean normalization is likely superior to cerebellar scaling for
interpretation of early-phase tau-PET images at the level of
individual patients. Nevertheless, in subjects with an overall
high load of neuronal injury or other reasons of a reduced
whole brain perfusion (e.g., after ischemic stroke), the
cerebellar scaling proved to be a viable alternative ap-
proach for normalization.
Based on the semiquantitative results, the visual anal-
ysis of summed [18F]PI-2620 perfusion-like images was
also performed with 3DSSP images generated by global
mean normalization. Both tau-PET early-phase images
(summed 0.5–2.5 min and R1) showed an overall high
visual agreement for the detection of neuronal injury
with the corresponding metabolic imaging. Less and
more experienced nuclear medicine physicians had no
or only minor disagreement between early-phase
[18F]PI-2620-PET and metabolic images in the majority
of cases, indicating broad clinical applicability. Different
patient preparation prior to injection of [18F]FDG (eye
patch and noise cancelling according to the EANM pro-
tocol [23]) and [18F]PI-2620 (room noise, no eye patch)
needs to be considered as a limitation.
In our population of subjects referred with suspected
tauopathies, half of all patients showed a significant neu-
ronal injury pattern. This highlights the potential of this
dual-phase protocol for evaluating two different bio-
markers with one examination. While the detailed addi-
tive value of early-phase tau-PET imaging ultimately
needs to be evaluated in larger samples, we already ob-
tained promising results in individual cases. The patient
with a final clinical diagnosis of frontotemporal demen-
tia shown in Fig. 3 was initially referred with suspected
AD, and the combination of tau-negativity together with
a frontal hypoperfusion pattern was in line with the clin-
ical presentation after 1-year follow-up. For the evalua-
tion of perfusion-like images as a surrogate of neuronal
injury, the comparison with metabolic imaging has the
restriction that even a metabolic correlate might not un-
equivocally represent the actually existing neuronal inju-
ry. Temporary neuronal dysfunctions, for example, in the
Table 3 Spearman’s rank
correlation coefficients (ρ)
between visual assessments of
[18F]FDG-PET and early-phase
[18F]PI-2620-PET; SUM,
summed image 0.5–2.5 min after
injection of [18F]PI-2620; LER,
less experienced reader; MER,
more experienced reader; R, right;
L, left; ND, neurodegeneration
LER1 LER2 LER3 MER1 MER2 MER3
FDG versus SUM ρ ρ ρ ρ ρ ρ
Likelihood of ND 0.661** 0.159 0.335 0.545** 0.404* 0.405*
Frontal R 0.666** 0.579** 0.407* 0.491* 0.403* 0.306
Frontal L 0.738** 0.576** 0.482* 0.550** 0.568** 0.525**
Parietal R 0.876** 0.641** 0.323 0.612** 0.398* 0.803**
Parietal L 0.717** 0.725** 0.478* 0.531** 0.359 0.659**
Temporal R 0.454* 0.517** 0.470* 0.677** 0.294 0.239
Temporal L 0.634** 0.399* 0.658** 0.566** 0.565** 0.321
Occipital R − 0.097 0.385 0.587** 0.676** 0.074 0.692**
Occipital L 0.280 0.476* 0.566** 0.852** 0.554** 0.557**
FDG versus R1 ρ ρ ρ ρ ρ ρ
Likelihood of ND 0.541** 0.267 0.526** 0.634** 0.598** 0.593**
Frontal R 0.366 0.447* 0.258 0.432* 0.255 0.326
Frontal L 0.732** 0.576** 0.600** 0.598** 0.558** 0.401*
Parietal R 0.756** 0.726** 0.614** 0.674** 0.508** 0.742**
Parietal L 0.617** 0.714** 0.724** 0.554** 0.654** 0.560**
Temporal R 0.577** 0.493 0.371 0.367 0.337 0.588**
Temporal L 0.670** 0.454* 0.706** 0.557** 0.747** 0.537**
Occipital R − 0.097 0.180 − 0.002 0.820** 0.286 0.731**
Occipital L 0.345 0.509** 0.598** 0.801** 0.684** 0.728**
*p < 0.05, **p < 0.01
Fig. 3 Representative 3D-SSP images (Z-score maps) of [18F]FDG-PET,
early-phase [18F]PI-26200.5–2.5min and [
18F]PI-2620R1 for three different
most likely diagnoses of neurodegenerative disorders: a Alzheimer’s
disease, b frontotemporal dementia, c progressive supranuclear palsy
(Richardson syndrome). Surface projections from R, right; L, left; LAT,
lateral; SUP, superior; INF, inferior; ANT, anterior; POST, posterior;
MED, medial
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context of a diaschisis or neuroinflammation, cannot be
differentiated from the presence of neuronal damage.
Both reduced metabolism in [18F]FDG-PET and reduced
perfusion in perfusion-phase images of different radiotracers
are influenced and partially caused by partial volume effects
and might not purely reflect the underlying neuronal injury.
Nevertheless, a close correlation with atrophy in magnetic
resonance imaging [34] or neuropathology findings [13] was
demonstrated for metabolic imaging via [18F]FDG. Therefore,
most classification schemes, such as ATN [12], list [18F]FDG-
PETas a surrogate of neuronal injury together with atrophy in
structural magnetic resonance imaging and total tau in cere-
brospinal fluid. Our findings clearly demonstrate that dual-
phase [18F]PI-2620-PET cannot only provide information on
“T” [22] but has also the potential to facilitate assessment of
“N”.
Conclusions
The present study demonstrates that early-phase imaging of
second-generation [18F]PI-2620 tau-PET can serve as a surro-
gate biomarker for neuronal injury as it shows excellent semi-
quantitative and visual agreement with metabolic imaging
using [18F]FDG-PET. Dynamic imaging or a dual time-point
protocol for tau-PET could replace additional [18F]FDG-PET
imaging by indexing two biomarkers in neurodegenerative
disease, the distribution of tau and the amount and regional
pattern of neuronal injury. The short time required for record-
ing perfusion-like images is a great advantage in terms of
patient comfort, examination time, radiation safety and cost-
effectiveness.
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